D. Levy

发表

Letting the patients speak: an in-depth, qualitative research-based investigation of factors relevant to health-related quality of life in real-world patients with hereditary angioedema using subcutaneous C1 inhibitor replacement therapy

W. Lumry, John T. Anderson, D. Levy, 2021, Allergy, Asthma & Clinical Immunology.

Effects of Continuous Plasma-Derived Subcutaneous C1-Esterase Inhibitor on Coagulation and Fibrinolytic Parameters

P. Keith, T. Machnig, T. Craig, 2020, Thrombosis and Haemostasis.

Advances in Hereditary Angioedema: The Prevention of Angioedema Attacks With Subcutaneous C1-Inhibitor Replacement Therapy

W. Lumry, D. Levy, L. Omert, 2020, Journal of infusion nursing : the official publication of the Infusion Nurses Society.

Long-Term Efficacy of Subcutaneous C1 Inhibitor in Pediatric Patients with Hereditary Angioedema

I. Hussain, M. Cicardi, I. Pragst, 2018, Pediatric allergy, immunology, and pulmonology.

Prevention of Hereditary Angioedema Attacks with a Subcutaneous C1 Inhibitor

William H. Yang, P. Keith, P. Kralickova, 2017, The New England journal of medicine.

Mitigating Disparity in Health-care Resources Between Countries for Management of Hereditary Angioedema

W. Aberer, W. Lumry, H. Farkas, 2021, Clinical Reviews in Allergy & Immunology.

Long-term efficacy and safety of subcutaneous C1-inhibitor in women with hereditary angioedema: subgroup analysis from an open-label extension of a phase 3 trial

H. Farkas, M. Cicardi, I. Pragst, 2020, Allergy, Asthma & Clinical Immunology.

Long-term health-related quality of life in patients treated with subcutaneous C1-inhibitor replacement therapy for the prevention of hereditary angioedema attacks: findings from the COMPACT open-label extension study

P. Keith, T. Machnig, J. Bernstein, 2021, Orphanet Journal of Rare Diseases.

Long-Term Outcomes with Subcutaneous C1-Inhibitor Replacement Therapy for Prevention of Hereditary Angioedema Attacks.

William H. Yang, P. Keith, J. Bernstein, 2019, The journal of allergy and clinical immunology. In practice.

Health-Related Quality of Life with Subcutaneous C1-Inhibitor for Prevention of Attacks of Hereditary Angioedema.

P. Keith, T. Machnig, J. Bernstein, 2018, The journal of allergy and clinical immunology. In practice.

Prophylactic use of an anti-activated factor XII monoclonal antibody, garadacimab, for patients with C1-esterase inhibitor-deficient hereditary angioedema: a randomised, double-blind, placebo-controlled, phase 2 trial

William H. Yang, P. Keith, W. Lumry, 2022, The Lancet.

Co-occurrence between C1 esterase inhibitor deficiency and autoimmune disease: a systematic literature review

P. Keith, G. Krishnarajah, T. Craig, 2020, Allergy, Asthma & Clinical Immunology.

Subcutaneous C1 inhibitor for prevention of attacks of hereditary angioedema: additional outcomes and subgroup analysis of a placebo-controlled randomized study

T. Machnig, J. Bernstein, W. Lumry, 2019, Allergy, Asthma & Clinical Immunology.

Correction to: Long-term health-related quality of life in patients treated with subcutaneous C1-inhibitor replacement therapy for the prevention of hereditary angioedema attacks: findings from the COMPACT open-label extension study

P. Keith, T. Machnig, J. Bernstein, 2021, Orphanet Journal of Rare Diseases.

Hereditary angioedema C1-esterase inhibitor replacement therapy and coexisting autoimmune disorders: findings from a claims database

H. Farkas, D. Supina, M. Fridman, 2020, Allergy, Asthma & Clinical Immunology.

Avulsion of the optic disc after a blow to swimming goggles.

D. Levy, 1999, Journal of pediatric ophthalmology and strabismus.

Long-Term Outcomes with Subcutaneous C1-Inhibitor Replacement Therapy for Prevention of Hereditary Angioedema Attacks.

William H. Yang, P. Keith, J. Bernstein, 2019, The journal of allergy and clinical immunology. In practice.